Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Overview of attention for article published in Applied Health Economics and Health Policy, November 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 15 X users

facebook: 1 Facebook page

Readers on

mendeley: 75 Mendeley

Summary X Facebook

So far, Altmetric has seen 19 X posts from 15 X users, with an upper bound of 68,767 followers.

Read more about a case study suggesting we need to reconsider current marketing authorisation models and approaches for cancer medicines in Europe: https://t.co/OaFeIdPTLx

31 Jan 2020

Reply Repost Favourite

https://t.co/zYVqdN5YcW

26 Nov 2019

Reply Repost Favourite

RT @cpontesg: It may be time to review early access systems, and to explore new avenues regarding who should pay or part pay for new treatm…

25 Nov 2019

Reply Repost Favourite

RT @cpontesg: Recently published: Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case o…

25 Nov 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 15 additional X posts.